<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>BELEODAQ (belinostat) for injection - for Healthcare Professionals (HCPs)</title>
    <meta name="description" content="In the next round against relapsed or refractory PTCL, fight on with BELEODAQ. It is an HDAC inhibitor available for relapsed/refractory PTCL.">
    <!-- Favicon -->
    <link rel="icon" href="https://beleodaq.com/hcp/wp-content/uploads/2019/05/cropped-favicon-Beleodaq-32x32.png" sizes="32x32">
    <!-- Google fonts -->
    <link rel="preconnect" href="https://fonts.gstatic.com">
    <link href="https://fonts.googleapis.com/css2?family=Open+Sans:wght@300;400;600;700;800&family=Raleway:wght@700&display=swap" rel="stylesheet">
    <!-- CSS Reset -->
    <link rel="stylesheet" href="css/reset.css">
    <!-- Stylesheet -->
    <link rel="stylesheet" href="css/safety.css">
</head>
<body>
    <!-- Header -->
    <header class="header">
        <!-- Indications and Usage -->
        <div class="indications">
            <h5 class="indications__title">Indications and Usage</h5>
            <p class="indications__body copyright">BELEODAQ is a histone deacetylase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon veriﬁcation and description of clinical beneﬁt in the conﬁrmatory trial.</p>
        </div>
        <!-- Navigation -->
        <nav class="nav">
            <!-- Logo -->
            <a class="nav__logo" href="index.html">
                <img src="https://beleodaq.com/hcp/wp-content/uploads/2019/04/logonew.png" alt="BELEODAQ® (belinostat) for injection: For injection in the treatment of relapsed or refractory PTCL">
            </a>
            <!-- Header Buttons -->
            <div class="nav__buttons">
                <!-- Site Buttons (redirecting to other parts of site) -->
                <ul class="site-buttons">
                    <li>
                        <a class="site-buttons__button p" href="#">
                            Important Safety Information
                        </a>
                    </li>
                    <li>
                        <a class="site-buttons__button p"
                        href="#">
                           Prescribing Information
                        </a>
                    </li>
                    <li>
                        <a class="site-buttons__button button--orange p" href="#">
                           Patient Site
                        </a>
                    </li>
                </ul>
                <!-- Nav Links and Dropdown Menus -->
                <ul class="navlinks">
                    <li>
                        <a class="navlinks__link p" href="ptcl.html">PTCL <br>Overview</a>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="about.html">About <br>Beleodaq</a>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="about.html">BELIEF <br>Trial</a>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="efficacy.html"><br>Efficacy</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    Study design
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Baseline Characteristics
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Response Rate
                                </a>
                             </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Duration of Response
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li class="active">
                        <a class="navlinks__link--active p" href="safety.html">Safety & Tolerability</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    Adverse Reactions
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Tolerability
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="#">Dosing & Administration</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    Dosing Schedule
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Dose Modifications
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="#">Access & Resources</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    STAR
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Resources
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="#">Contact <br>Us</a>
                    </li>
                </ul>
            </div>
        </nav>
    </header>
    <!-- Main -->
    <main>
        <h2 class="primary">Duration of Exposure and Incidence of Adverse Events (AEs)</h2>
       
        <h3 class="secondary-variant">AEs occurring in ≥10% of patients (N = 129) with R/R PTCL (NCI-CTCAE grades 1 to 4)<sup>1</sup></h3>

        <div class="patient-aes">
            <img src="assets/svg/safety-chart.svg" alt="AEs occurring in ≥10% of patients (N = 129) with R/R PTCL (NCI-CTCAE grades 1 to 4)">
            <ul>
                <li>
                    <h4 class="light">Most patients (113 of 129) remained on the target dose (1000 mg/m2)<sup>1,2</sup>
                    <ul>
                        <li>Dosage adjustments due to AEs occurred in 16 of 129 patient treated with BELEODAQ</li>
                    </ul>
                    </h4>
                </li>
                <li>
                    <h4 class="light">The relative dose intensity (doses administered vs planned) was 98%<sup>2</sup></h4>
                </li>
                <li>
                    <h4 class="light">Treatment duration ranged from 1 to 33 cycles (median, 2 cycles)<sup>1,2</sup></h4>
                </li>
                <li>
                    <h4 class="light">Twenty-five patients (19.4%) discontinued treatment with BELEODAQ due to AEs<sup>1</sup>
                        <ul>
                            <li>The AEs reported most frequently as the reason for discontinuation of treatment included anemia, febrile neutropenia, fatigue, and multi-organ failure</li>
                        </ul>
                    </h4>
                </li>
                <li>
                    <h4 class="light">Treatment-emergent AEs (TEAEs) occurred in 97% of patients and were generally mild to moderate in severity<sup>2</sup>
                    <ul>
                        <li>The most common AEs were nausea, fatigue, pyrexia, anemia, and vomiting</li>
                    </ul></h4>
                </li>
                <li>
                    <h4 class="light">Grade 3/4 AEs occurring in ≥5% of patients (N = 129) were anemia (11%), thrombocytopenia (7%), dyspnea (6%), and fatigue (5%)<sup>1</sup></h4>
                </li>
                <li>
                    <h4 class="light">47% (n = 61) experienced serious AEs (SAEs)<sup>1,2</sup>
                    <ul>
                        <li>
                            No clinically meaningful difference in SAEs was observed in patients based on age (&lt;65 years vs &lt;65 years or &lt;75 years vs ≥75 years)
                        </li>
                    </ul></h4>
                </li>
            </ul>
        </div>

        <p class="light">NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events. 
            Note: AEs are listed by order of incidence in the all-grades category first, then in the grades 3 to 4 category; measured by NCI-CTCAE version 3.0.
        </p>

        <h2 class="primary">
            Tolerability Established With the BELIEF Trial<sup>1,2</sup>
        </h2>
        <h3 class="secondary-variant">Most patients tolerated the target dose of BELEODAQ<sup>1,2</sup></h3>
        <div class="tolerability-data">
            <div class="data_figure">
                <h4 class="light">
                    <span class="jumbo secondary">12<sup>%</sup></span>
                    <span class="big secondary">OF PATIENTS</span>
                    receiving BELEODAQ <span class="secondary semibold">required a dosage reduction</span> due to AEs
                </h4>
            </div>
            <img src="assets/svg/safety-graph.svg" alt="Most patients tolerated the target dose of BELEODAQ"/>
            <div class="data_figure">
                <h4 class="light">
                    <span class="jumbo primary">88<sup>%</sup></span>
                    <span class="big primary">OF PATIENTS</span>
                    receiving BELEODAQ <span class="primary semibold">did not require a dosage reduction</span> due to AEs
                </h4>
            </div>
        </div>
        <div class="heartline">
            <img src="assets/svg/heartline-graphic.svg" alt="heartline graphic"/>
            <h4 class="secondary">In studies, BELEODAQ® (belinostat) has not been associated with clinically relevant changes in heart rate or PR- or QRS-interval duration<sup>2</sup>
            </h4>
        </div>
        <h4 class="secondary">BELEODAQ is the only agent that the FDA has approved for the treatment of R/R PTCL that was studied in patients (N = 120) with platelet counts down to 50,000/μL<sup>2</sup></h4>
        <ul>
            <li>
                <h4 class="light">
                R/R PTCL patients with <span class="secondary semibold">platelet counts &lt;100,000/μL</span> are typically <span class="secondary semibold">ineligible for clinical trials<sup>3</sup></span>
                </h4>
            </li>
        </ul>
        <p class="light">1. BELEODAQ® [Prescribing Information], Acrotech Biopharma, LLC; January 2020. 2. O’Connor O, et al. J Clin Oncol. 2015;33:2492-2499. 3. Savage KJ, et al. Blood. 2014:124:3075. doi.org/10.1182/blood.V124.21.3075.3075.
        </p>
        <div class="button-group">
            <a href="efficacy2.html" class="button secondary">&larr; Efficacy</a>
            <a href="#" class="button">Dosing & Administration &rarr;</a>
        </div>
    </main>
    <!-- ISI -->
    <footer>
        <section class="isi">
            <div>
                <h5 class="isi__header">Select Important Safety Information</h5>
                <p class="isi__body copyright"><span class="isi__body--bold ">Warnings and Precautions</span>
                    BELEODAQ can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment, and modify dosage as necessary.</p>
            </div>
            <a class="isi__button p" href="#">
                See More <span>&uarr;</span>
            </a>
        </section>
    </footer>
    <!-- Vanilla JS -->
    <script src="js/app.js"></script>
</body>
</html>